0
     

Report Added
Report already added
Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 8, 8, 9, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thromboembolism - Overview
Thromboembolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thromboembolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thromboembolism - Companies Involved in Therapeutics Development
Acticor Biotech SAS
Alexion Pharmaceuticals Inc
Alfasigma SpA
Anthos Therapeutics Inc
Bayer AG
Bio-Synectics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
China Biologic Products Holdings Inc
China Resources Emde Biological Pharmaceutical Co Ltd
CSPC Pharmaceutical Group Ltd
Espero BioPharma Inc
EVAS Therapeutics LLC
GC Pharma
Indiana Lysis Technologies LLC
Ionis Pharmaceuticals Inc
IPCA Laboratories Ltd
Jiangsu Hengrui Medicine Co Ltd
KLUS Pharma Inc
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Ono Pharmaceutical Co Ltd
PharmaDiall
Supergene LLC
Tasly Pharmaceutical Group Co Ltd
Techfields Pharma Co Ltd
Tetherex Pharmaceuticals Corp
Tianjin Pharmaceuticals Group Co Ltd
Translational Sciences Inc
Verseon Corp
Thromboembolism - Drug Profiles
A-336 - Drug Profile
Product Description
Mechanism Of Action
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
antithrombin III (human) - Drug Profile
Product Description
Mechanism Of Action
apixaban - Drug Profile
Product Description
Mechanism Of Action
History of Events
AT-10 - Drug Profile
Product Description
Mechanism Of Action
betrixaban - Drug Profile
Product Description
Mechanism Of Action
History of Events
dabigatran etexilate mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
DD-217 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs for Pulmonary Embolism - Drug Profile
Product Description
Mechanism Of Action
enoxaparin sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
GC-2107 - Drug Profile
Product Description
Mechanism Of Action
History of Events
glenzocimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
HR-17020 - Drug Profile
Product Description
Mechanism Of Action
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
History of Events
KKM-183A - Drug Profile
Product Description
Mechanism Of Action
Lysimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
milvexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
ONO-7684 - Drug Profile
Product Description
Mechanism Of Action
History of Events
osocimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
reteplase - Drug Profile
Product Description
Mechanism Of Action
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
History of Events
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
SelK-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHR-2285 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Staphylokinase - Drug Profile
Product Description
Mechanism Of Action
History of Events
sulodexide - Drug Profile
Product Description
Mechanism Of Action
History of Events
SYHA-136 - Drug Profile
Product Description
Mechanism Of Action
TAP-ANV - Drug Profile
Product Description
Mechanism Of Action
History of Events
tecarfarin sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
TF-0023 - Drug Profile
Product Description
Mechanism Of Action
urokinase - Drug Profile
Product Description
Mechanism Of Action
History of Events
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YG-001 - Drug Profile
Product Description
Mechanism Of Action
Zifa-01 - Drug Profile
Product Description
Mechanism Of Action
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Dec 20, 2021: FDA approves two new indications for XARELTO (rivaroxaban) to help prevent and treat blood clots in pediatric patients
Nov 16, 2021: Janssen-BMS’ drug reduces venous thromboembolism risk in Phase II TKR trial
Nov 10, 2021: Hengrui Medicine's new anti-thrombotic drug, a new class 1 drug SHR2285 tablets phase II clinical trial approved
Jun 21, 2021: FDA approves first oral blood thinning medication for children
May 10, 2021: Bayer announces late-breaking presentations which include data from VOYAGER PAD (Xarelto)
Mar 11, 2021: Lee’s Pharmaceutical: Voluntary announcement - Update on an investigational direct oral anticoagulant
Feb 01, 2021: Bayer receives approval in the UK for Xarelto (rivaroxaban) to treat children with venous thromboembolism (VTE) and to Prevent VTE recurrence
Jan 22, 2021: Japan approves rivaroxaban (Xarelto) to treat children with venous thromboembolism and to prevent recurrence
Nov 16, 2020: Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Nov 13, 2020: Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children
Mar 29, 2020: Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery
Mar 29, 2020: Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery
Mar 20, 2020: Janssen Highlight presentation on XARELTO at American College of Cardiology Scientific Session
Feb 21, 2020: Secondary analysis confirms safety of blood thinning agent
Dec 07, 2019: Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Thromboembolism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Thromboembolism - Pipeline by Acticor Biotech SAS, 2022
Thromboembolism - Pipeline by Alexion Pharmaceuticals Inc, 2022
Thromboembolism - Pipeline by Alfasigma SpA, 2022
Thromboembolism - Pipeline by Anthos Therapeutics Inc, 2022
Thromboembolism - Pipeline by Bayer AG, 2022
Thromboembolism - Pipeline by Bio-Synectics Inc, 2022
Thromboembolism - Pipeline by Boehringer Ingelheim International GmbH, 2022
Thromboembolism - Pipeline by Bristol-Myers Squibb Co, 2022
Thromboembolism - Pipeline by China Biologic Products Holdings Inc, 2022
Thromboembolism - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2022
Thromboembolism - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
Thromboembolism - Pipeline by Espero BioPharma Inc, 2022
Thromboembolism - Pipeline by EVAS Therapeutics LLC, 2022
Thromboembolism - Pipeline by GC Pharma, 2022
Thromboembolism - Pipeline by Indiana Lysis Technologies LLC, 2022
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, 2022
Thromboembolism - Pipeline by IPCA Laboratories Ltd, 2022
Thromboembolism - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Thromboembolism - Pipeline by KLUS Pharma Inc, 2022
Thromboembolism - Pipeline by Kolmar Korea Co Ltd, 2022
Thromboembolism - Pipeline by Laboratorios Farmaceuticos Rovi SA, 2022
Thromboembolism - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Thromboembolism - Pipeline by PharmaDiall, 2022
Thromboembolism - Pipeline by Supergene LLC, 2022
Thromboembolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
Thromboembolism - Pipeline by Techfields Pharma Co Ltd, 2022
Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, 2022
Thromboembolism - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2022
Thromboembolism - Pipeline by Translational Sciences Inc, 2022
Thromboembolism - Pipeline by Verseon Corp, 2022
Thromboembolism - Dormant Projects, 2022
Thromboembolism - Dormant Projects, 2022 (Contd..1)
Thromboembolism - Discontinued Products, 2022

List of Figures
Number of Products under Development for Thromboembolism, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Thromboembolism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User - Global Forecast to 2029

Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Oncology), Modality (MRI, CT, X-ray, Ultrasound), End User - Global Forecast to 2029

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease, Transfusion], Research), End User, and Geography - Forecast to 2029

HLA Typing Market by Product (Instruments, Software), Technology (Molecular [PCR, Sequencing [Sangers, NGS]], Serology), Application (Diagnostics [Cross Match, Cancer, Infectious Disease, Transfusion], Research), End User, and Geography - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

Medical Aesthetics Market by Product (Facial Aesthetics, Body Contouring, Cosmetic Implant, Physician Dispensed Cosmeceuticals, Skin Aesthetic, Thread Lift), End User (Hospitals, Clinics, & Medical Spas, Beauty Centers, & Home Care) - Forecast to 2029

Medical Aesthetics Market by Product (Facial Aesthetics, Body Contouring, Cosmetic Implant, Physician Dispensed Cosmeceuticals, Skin Aesthetic, Thread Lift), End User (Hospitals, Clinics, & Medical Spas, Beauty Centers, & Home Care) - Forecast to 2029

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

United Kingdom Hospital Market, By Ownership (Public v/s Private), By Type (General, Multispecialty, Specialty), By Type of Services (In-Patient Services v/s Out-Patient Services), By Bed Capacity (Above 500, 100-500, up to 100), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F

Saudi Arabia Magnetic Resonance Imaging Market, By Field Strength (High-Field MRI Systems, Low-to-Mid Field MRI Systems, Very-High-Field MRI Systems), By Type (Fixed v/s Mobile), By Architecture (Closed v/s Open), By Source (Import v/s Domestic), By Application (Brain and Neurological, Oncology, Spine and Musculoskeletal, Abdominal, Cardiac & Others), By End User (Hospitals, Imaging Centers, Ambulatory Surgical Centers & Others), By Region, Competition, Forecast & Opportunities, 2017-2027F